{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:37Z","timestamp":1787021137025,"version":"build-2736575974"},"reference-count":71,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Squamous cell carcinoma of the anal canal (SCAC) is a rare, human papillomavirus\u2013driven malignancy with a rising global incidence and an increasingly dynamic therapeutic landscape. This review summarizes recent advances and current evidence in the management of SCAC, with a focus on immunotherapy, systemic treatment strategies, and optimization of curative-intent approaches. For locally advanced SCAC, concurrent chemoradiotherapy with fluorouracil and mitomycin C remains the standard of care, on the basis of multiple randomized trials demonstrating improved disease control and organ preservation compared with radiotherapy alone. These studies also show that treatment intensification with alternative chemotherapy, induction therapy, or radiation dose escalation does not improve outcomes. Given the curative intent, maintaining quality of life is a key consideration, and current studies are evaluating radiation dose optimization to reduce treatment-related toxicity, as well as the integration of immunotherapy to improve treatment efficacy. In metastatic SCAC, the combination of carboplatin and paclitaxel is the established first-line chemotherapy backbone. The addition of the PD-1 inhibitor retifanlimab to chemotherapy has demonstrated improved clinical outcomes and is now a preferred first-line approach. In the treatment-refractory setting, anti\u2013PD-1 monotherapy provides modest response rates and remains a standard option for immunotherapy-na\u00efve patients. Together, these findings summarize the current evidence base guiding the management of SCAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-516572","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:59:41Z","timestamp":1779998381000},"source":"Crossref","is-referenced-by-count":1,"title":["Updates on Management of Anal Cancer: A New Era Has Begun"],"prefix":"10.1200","volume":"46","author":[{"given":"Shalini","family":"Fernando","sequence":"first","affiliation":[{"name":"Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Centre, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yu","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Centre, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Centre (VICC), Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Lessans","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Centre (VICC), Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-9919","authenticated-orcid":true,"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.04.013"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz219"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0044"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs491"},{"key":"e_1_3_2_7_2","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami F","year":"2017","unstructured":"Islami F, Ferlay J, Lortet-Tieulent J, et al: International trends in anal cancer incidence rates. Int J Epidemiol 46:924-938, 2017","journal-title":"Int J Epidemiol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6526a1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24215"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24116"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711063371904"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3464"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00946-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0091"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102254"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200245"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-021-00131-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830401)51:7<1291::AID-CNCR2820510719>3.0.CO;2-R"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02586980"},{"key":"e_1_3_2_20_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Version 5.2025","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","unstructured":"National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Version 5.2025. Plymouth Meeting, PA, National Comprehensive Cancer Network, 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2040"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2527"},{"key":"e_1_3_2_24_2","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08","volume":"2","author":"John M","year":"1996","unstructured":"John M, Pajak T, Flam M, et al: Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08. Cancer J Sci Am 2:205-2011, 1996","journal-title":"Cancer J Sci Am"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25188"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4837"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30071-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.012"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.09.023"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00213-X"},{"key":"e_1_3_2_34_2","volume-title":"Study Record:","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Study Record:NCT05902533. Bethesda, MD, National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05902533"},{"key":"e_1_3_2_35_2","volume-title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer (DECREASE) (NCT04166318)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer (DECREASE) (NCT04166318). Bethesda, MD, National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04166318"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00605-9"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.1"},{"key":"e_1_3_2_38_2","volume-title":"Radiochemotherapy \u00b1 Durvalumab for Locally-advanced Anal Carcinoma (RADIANCE) (NCT04230759)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Radiochemotherapy \u00b1 Durvalumab for Locally-advanced Anal Carcinoma (RADIANCE) (NCT04230759). Bethesda, MD, National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04230759"},{"key":"e_1_3_2_39_2","volume-title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II\u2013IIIB Anal Cancer (NCT03233711)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II\u2013IIIB Anal Cancer (NCT03233711). Bethesda, MD, National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03233711"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.035"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050343"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.015"},{"key":"e_1_3_2_43_2","volume-title":"SEER Cancer Statistics Review (CSR) 1975-2016","author":"Howlader N","year":"2019","unstructured":"Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review (CSR) 1975-2016. Bethesda, MD, National Cancer Institute, 2019"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2563"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03266"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920975356"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00382-4"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002996"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100529"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060937"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00081-0"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00631-2"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2025.101207"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3614"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00929"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1512"},{"key":"e_1_3_2_61_2","volume-title":"Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment. Bethesda, MD, National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT06669572"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001395"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6998"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.4"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad085"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.09.005"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw152"},{"key":"e_1_3_2_68_2","unstructured":"Krop IE Jegede OA Grilley-Olson JE et al: Phase II study of taselisib in PIK3CA-mutated solid tumors other than breast and squamous lung cancer: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol I. JCO Precis Oncol 10.1200\/PO.21.00424"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0060"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1309\/X4UADHVN317V2XMW"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1810573"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1159\/000452766"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-516572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:59:45Z","timestamp":1780430385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-516572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-516572"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-516572","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e516572"}}